Resources Archive - Page 32 of 50

Jurkat Reporter Cell Lines for Immunotherapy Drug Screening

WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening. Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc...

Discovery of Novel GST Inhibitors Identified from a DNA-Encoded Library

WuXi AppTec scientists recently contributed to a study which led to the discovery and optimization of a novel series of...

Discovery and Characterization of Proteolysis Targeting Chimeras: Tissue Transglutaminase

Tissue transglutaminase (TG2) is a multifunctional enzyme activated in several pathological conditions, including cancer. WuXi AppTec recently contributed to a...

Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical...

One Stop Target-to-Hit Platform: PIK3CA–PIK3R1

Within the PI3K family, the heterodimer protein comprising the p110-α and p85-α catalytic/regulatory subunits (encoded by PIK3CA and PIK3R1) are...

One Stop Target-to-Hit Platform: Protein arginine methyltransferase 5 (PRMT5)

Protein arginine methyltransferase 5 (PRMT5) is an enzyme which plays an essential role in a wide range of cellular processes. ...

One Stop Target-to-Hit Platform: Cyclin-dependent kinase 2 (CDK2)

Cyclin-dependent kinase 2 (CDK2) and its respective cyclin E1 and cyclin A2 complexes are essential to driving abnormal growth processes...

One Stop Target-to-Hit Platform: Werner Syndrome Helicase (WRN)

Werner syndrome helicase (WRN) is a key drug target for cancers with microsatellite instability. To support the discovery of potent...

Emerging Modalities in Drug Discovery

In this webinar, we present the latest advances and challenges facing researchers focused on new and emerging modalities in drug...

Knowledge Library